Larvol Delta - Investigation-of-a-Remibrutinib-and-Omalizumabbased-Treatment-Algorithm-in-Adult-Patients-With-Chronic-Spontaneous-Urticaria-Inadequately-Controlled-by-H1antihistamines-Within-24-Weeks

Rhapsido (remibrutinib) - Novartis

Xolair (omalizumab) - Roche, Novartis

http://clinicaltrials.gov/ct2/show/NCT07816328

Sep 12, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next